Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 59 Published: February 28, 2022 Report Code: GMDGDHC22033IDB

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or rarely occurring seizures. The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation, drugs, and hypoxia.

The Hepatic encephalopathy drugs in development market report provides an overview of the Hepatic Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

What are the targets of the Hepatic Encephalopathy pipeline drugs market?

The targets of the Hepatic Encephalopathy pipeline drugs market are DNA Directed RNA Polymerase, DNA Directed RNA Polymerase Subunit Beta, DNA Gyrase, DNA Topoisomerase IV, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, RNA Polymerase, and Serum Albumin.

Hepatic Encephalopathy pipeline drugs market, by targets

Hepatic Encephalopathy pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Hepatic Encephalopathy pipeline drugs market?

The mechanisms of action of the Hepatic Encephalopathy pipeline drugs market are DNA Directed RNA Polymerase Inhibitor, DNA Directed RNA Polymerase Subunit Beta Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAntagonist, RNA Polymerase Inhibitor, and Serum Albumin Replacement.

Hepatic Encephalopathy pipeline drugs market, by mechanisms of action

Hepatic Encephalopathy pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Hepatic Encephalopathy pipeline drugs market?

The routes of administration in the Hepatic Encephalopathy pipeline drugs market are oral, intravenous, intraperitoneal, and rectal.

Hepatic Encephalopathy pipeline drugs market, by routes of administration

Hepatic Encephalopathy pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Hepatic Encephalopathy pipeline drugs market?

The molecule types in the Hepatic Encephalopathy pipeline drugs market are small molecule, biologic, blood derivative, and polysaccharide.

Hepatic Encephalopathy pipeline drugs market, by molecule types

Hepatic Encephalopathy pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Hepatic Encephalopathy pipeline drugs market?

Some of the key companies in the Hepatic Encephalopathy pipeline drugs market are Alfasigma SpA, Axcella Health Inc, Cosmo Pharmaceuticals NV, Grifols SA, Kaleido Biosciences Inc, Neuropathix Inc, Rebiotix Inc, Takeda Pharmaceutical Co Ltd, TenNor Therapeutics Ltd, Umecrine Cognition AB, Vedanta Biosciences Inc, and Versantis AG.

Hepatic Encephalopathy pipeline drugs market, by key companies

Hepatic Encephalopathy pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets DNA Directed RNA Polymerase, DNA Directed RNA Polymerase Subunit Beta, DNA Gyrase, DNA Topoisomerase IV, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, RNA Polymerase, and Serum Albumin
Mechanisms of Action DNA Directed RNA Polymerase Inhibitor, DNA Directed RNA Polymerase Subunit Beta Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAntagonist, RNA Polymerase Inhibitor, and Serum Albumin Replacement
Routes of Administration Oral, Intravenous, Intraperitoneal, and Rectal
Molecule Types Small Molecule, Biologic, Blood Derivative, and Polysaccharide
Key Companies Alfasigma SpA, Axcella Health Inc, Cosmo Pharmaceuticals NV, Grifols SA, Kaleido Biosciences Inc, Neuropathix Inc, Rebiotix Inc, Takeda Pharmaceutical Co Ltd, TenNor Therapeutics Ltd, Umecrine Cognition AB, Vedanta Biosciences Inc, and Versantis AG

This report provides:

  • A snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
  • Reviews of pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • Evaluation of Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Key Players

Alfasigma SpA

Axcella Health Inc

Cosmo Pharmaceuticals NV

Grifols SA

Kaleido Biosciences Inc

Neuropathix Inc

Rebiotix Inc

Takeda Pharmaceutical Co Ltd

TenNor Therapeutics Ltd

Umecrine Cognition AB

Vedanta Biosciences Inc

Versantis AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatic Encephalopathy – Overview

Hepatic Encephalopathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hepatic Encephalopathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatic Encephalopathy – Companies Involved in Therapeutics Development

Alfasigma SpA

Axcella Health Inc

Cosmo Pharmaceuticals NV

Grifols SA

Kaleido Biosciences Inc

Neuropathix Inc

Rebiotix Inc

Takeda Pharmaceutical Co Ltd

TenNor Therapeutics Ltd

Umecrine Cognition AB

Vedanta Biosciences Inc

Versantis AG

Hepatic Encephalopathy – Drug Profiles

albumin (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

AXA-1665 – Drug Profile

Product Description

Mechanism Of Action

History of Events

golexanolone – Drug Profile

Product Description

Mechanism Of Action

History of Events

KB-174 – Drug Profile

Product Description

Mechanism Of Action

History of Events

KLS-13019 – Drug Profile

Product Description

Mechanism Of Action

History of Events

KLS-13023 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RBX-2660 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RBX-7455 – Drug Profile

Product Description

Mechanism Of Action

History of Events

rifamycin sodium CR – Drug Profile

Product Description

Mechanism Of Action

History of Events

rifaximin – Drug Profile

Product Description

Mechanism Of Action

History of Events

rifaximin SSD – Drug Profile

Product Description

Mechanism Of Action

History of Events

TAK-039 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TNP-2092 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VE-303 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-02 – Drug Profile

Product Description

Mechanism Of Action

Hepatic Encephalopathy – Dormant Projects

Hepatic Encephalopathy – Discontinued Products

Hepatic Encephalopathy – Product Development Milestones

Featured News & Press Releases

Jan 18, 2022: Neuropathix receives patent grant from India for its novel anti-inflammatory compounds

Jan 11, 2022: Karolinska Development’s portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms

Nov 02, 2021: Axcella Therapeutics announces upcoming presentation of AXA1665 at AASLD’s The Liver Meeting 2021

Jul 14, 2021: Karolinska Development’s portfolio company Umecrine Cognition raises capital through a successful share issue

Jun 30, 2021: Axcella announces initiation of EMMPOWER phase 2 clinical trial of AXA1665

May 24, 2021: Positive clinical data about Axcella’s AXA1665 candidate for overt hepatic encephalopathy highlighted in oral presentation at DDW 2021

Apr 22, 2021: Axcella announces upcoming oral presentation at digestive disease week (ddw) 2021

Apr 22, 2021: Karolinska Development’s portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal

Dec 29, 2020: Karolinska Development increases book value of Umecrine Cognition by SEK 234 million

Oct 07, 2020: Kaleido Biosciences to present data from candidate KB174 at The Liver Meeting 2020

Oct 06, 2020: Kannalife adds to its global IP estate receiving patent grant from Canada for its novel anti-inflammatory compounds

Sep 02, 2020: Karolinska Development’s portfolio company Umecrine Cognition presents results from clinical phase 2a study at AALSD International Liver meeting

Aug 27, 2020: Kaleido Biosciences announces presentation of data for microbiome metabolic therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress (EASL)

Aug 25, 2020: Kannalife receives patent grants in additional European territories

Aug 05, 2020: Axcella reports positive top-line data from AXA1665-002

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatic Encephalopathy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hepatic Encephalopathy – Pipeline by Alfasigma SpA, 2022

Hepatic Encephalopathy – Pipeline by Axcella Health Inc, 2022

Hepatic Encephalopathy – Pipeline by Cosmo Pharmaceuticals NV, 2022

Hepatic Encephalopathy – Pipeline by Grifols SA, 2022

Hepatic Encephalopathy – Pipeline by Kaleido Biosciences Inc, 2022

Hepatic Encephalopathy – Pipeline by Neuropathix Inc, 2022

Hepatic Encephalopathy – Pipeline by Rebiotix Inc, 2022

Hepatic Encephalopathy – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Hepatic Encephalopathy – Pipeline by TenNor Therapeutics Ltd, 2022

Hepatic Encephalopathy – Pipeline by Umecrine Cognition AB, 2022

Hepatic Encephalopathy – Pipeline by Vedanta Biosciences Inc, 2022

Hepatic Encephalopathy – Pipeline by Versantis AG, 2022

Hepatic Encephalopathy – Dormant Projects, 2022

Hepatic Encephalopathy – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Hepatic Encephalopathy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.